17d agoStocktwits NewsBULLISH 67Earnings
SJM, ZYME Stocks Hit 52-Week High – What’s Driving The Surge Today?
SJM raised its annual outlook following a quarterly earnings beat, while ZYME gained on price-target hikes tied to Ziihera’s FDA approval.
Archived explainer. For the current picture see today's ZYME page.
Why Is ZYMEWORKS INC (ZYME) Stock Up Today?
By the Top Tier Newswire AI Desk · August 27, 2026 at 12:21 AM ET · reviewed against 9 wire stories
ZYMEWORKS INC (ZYME) is up +6.68% in the latest session. Our newswire has captured 9 stories on ZYME across 6 sources in the last 36 hours, with AI sentiment reading bullish (avg 65/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
ZYME stock surged 6.68% to $29.30 on August 27, driven by the U.S. Food and Drug Administration’s approval of Jazz Pharmaceuticals’ Ziihera regimen for first-line treatment of HER2-positive gastroesophageal adenocarcinoma. The milestone triggered a $250 million payment to Zymeworks and raised expectations for future royalty revenue. Analysts responded with price target increases, and the stock hit a new 52-week high.
What Happened
The FDA’s approval of Ziihera marked a major development for Zymeworks, unlocking a $250 million milestone payment and expanding its potential for royalties. This regulatory win also reinforced the company’s oncology pipeline and positioned Ziihera as a key treatment in the HER2+ gastroesophageal cancer market. In response, H.C. Wainwright raised its price target to $55, while Citi increased its target to $38. Citizens reiterated its Market Outperform rating with a $32 price target. The stock’s surge followed a broader trend of analysts and investors reacting positively to the approval and its financial implications.
What The Data Shows
ZYME has gained 17.1% over the last eight trading sessions, moving from $25.31 to $29.65. The stock closed at $29.30, just below its 52-week high of $30.50. On August 27, it printed 20 fresh 52-week highs, indicating strong institutional and retail interest. The company’s fundamentals remain challenging, with a trailing twelve-month revenue decline of 69.8% and a net margin of -404.0%. Despite these challenges, the recent approval and analyst upgrades have shifted investor sentiment.
What To Watch
Zymeworks does not have an upcoming earnings date in the provided data. Investors should monitor the breadth of analyst coverage and any further price target adjustments. Continued momentum may depend on the commercial performance of Ziihera and the company’s ability to leverage the expanded royalty stream.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
ZYME by the numbers
Last: $29.30Session: +6.68%7 sessions: +10.97%Coverage: 9 stories / 6 sourcesAI sentiment: 65/100 (bullish)Mkt cap: $2.0B52w: $13.60 to $30.50
The headlines behind the move
17d agoMarketChameleonBULLISH 73Product/PR
FDA Approval of Ziihera Ushers in New Era for Zymeworks: $250M Windfall, Expanded Royalties, and Strengthened Oncology Pipeline August 26, 2026
Zymeworks receives a $250 million milestone payment following FDA approval of Ziihera for first-line HER2+ gastroesophageal adenocarcinoma, unlocking the potential for over $1.4 billion in future milestones and royalties while diversifying its cancer treatment pipeline.
17d agoSeeking AlphaBULLISH 73General
Zymeworks moves higher as Street cheers Ziihera regimen approval
Zymeworks jumps on FDA approval of Jazz’s Ziihera regimens, triggering a $250M milestone and boosting royalty outlook. Read more here.
18d agoInvesting.com Analyst RatingsBULLISH 61Analyst
H.C. Wainwright raises Zymeworks stock price target to $55 on FDA approval
H.C. Wainwright raises Zymeworks stock price target to $55 on FDA approval
18d agoThe FlyBULLISH 61Analyst
Zymeworks price target raised to $38 from $37 at Citi
18d agoThe FlyBULLISH 61Analyst
Zymeworks price target raised to $55 from $51 at H.C. Wainwright
18d agoInvesting.com Analyst RatingsBULLISH 56Analyst
Zymeworks stock rating reiterated at Market Outperform by Citizens
Zymeworks stock rating reiterated at Market Outperform by Citizens
18d agoStocktwits NewsBULLISH 67Product/PR
JAZZ, ONC, ZYME Stocks In Focus After FDA Approves Gastroesophageal Cancer Therapy
The FDA approved Jazz Pharma’s Ziihera with chemotherapy, with or without BeOne’s Tevimbra, as an initial treatment for advanced HER2-positive gastroesophageal cancer.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on ZYME: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier ZYME move explainers: 2026-08-27 · 2026-08-26